Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children
Corresponding Author
Jennifer H. Foster
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Correspondence
Jennifer H. Foster, Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Cancer Center/Baylor College of Medicine, 6701 Fannin St, MWT, Suite 1510.00, Houston, Texas 77030, USA.
Email: [email protected]
Search for more papers by this authorAndrew Sher
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorVictor Seghers
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorJay Poston
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorDonald Wells
Dell Children's Medical Center, Austin, Texas, USA
Search for more papers by this authorEbrahim S. Delpassand
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, USA
Search for more papers by this authorSamara Potter
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorPriya Mahajan
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorRajkumar Venkatramani
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorCorresponding Author
Jennifer H. Foster
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Correspondence
Jennifer H. Foster, Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Cancer Center/Baylor College of Medicine, 6701 Fannin St, MWT, Suite 1510.00, Houston, Texas 77030, USA.
Email: [email protected]
Search for more papers by this authorAndrew Sher
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorVictor Seghers
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorJay Poston
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorDonald Wells
Dell Children's Medical Center, Austin, Texas, USA
Search for more papers by this authorEbrahim S. Delpassand
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, USA
Search for more papers by this authorSamara Potter
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorPriya Mahajan
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorRajkumar Venkatramani
Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorAbstract
Neuroendocrine tumors (NETs) of the pancreas and midgut are extremely rare in children, and patients presenting with metastatic disease have poor survival. Given this rarity, treatments are extrapolated from guidelines for adults with NET. Recent clinical trials in adults with NETs have shown that the addition of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE resulted in a disease control rate of nearly 80%, with minimal side effects. We report our experience using 177Lu-DOTATATE to treat two pediatric patients with metastatic NET.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.
REFERENCES
- 1Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GKD, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975–2006. Pediatr Blood Cancer. 2011; 56(1): 50-57.
- 2Redlich A, Wechsung K, Boxberger N, Leuschner I, Vorwerk P. Extra-appendiceal neuroendocrine neoplasms in children - data from the GPOH-MET 97 study. Klin Padiatr. 2013; 225(6): 315-319.
- 3Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013; 42(4): 557-577.
- 4Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001; 28(7): 836-846.
- 5Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020; 146(6): 1533-1543.
- 6Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017; 376(2): 125-135.
- 7Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018; 36(25): 2578-2584.
- 8Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124-2130.
- 9Gains JE, Bomanji JB, Fersht NL, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011; 52(7): 1041-1047.
- 10Gains JE, Moroz V, Aldridge MD, et al. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020; 47(10): 2348-2357.
- 11Kong G, Hofman MS, Murray WK, et al. Initial experience with Gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol. 2016; 38(2): 87-96.
- 12Tao L, Chen Y, Shi X, Yu G, Yin W, Huang Y. Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma. Virchows Arch. 2020; 477(4): 573-579.
- 13Rostomily RC, Elias M, Deng M, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 2006; 28(4): 305-312.
- 14Remke M, Hering E, Gerber NU, et al. Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst. 2013; 29(8): 1253-1262.
